Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Chardan Capital Markets Upgrades Arbutus Biopharma (ABUS) to Buy
-
WPCS Closes $968,000 Financing
-
Ritter Pharma (RTTR): Cutting PT After Phase II Data Fails To Meet Endpoint - Chardan
-
Pre-Open Movers 03/28: (PSIX) (CARA) (SB) Higher; (CYRX) (ORIG) (MEET) Lower (more...)
-
Biocept (BIOC) to Sell 4.32M Shares at $2.15 with Warrants
-
Biocept Announces Pricing of $9.3 Million Financing
-
After-Hours Stock Movers 03/27: (PSIX) (OCN) (RHT) Higher; (CYRX) (EVH) (STOR) Lower (more...)
-
Chardan Capital Markets Starts CRISPR Therapeutics (CRSP) at Buy
-
Chardan Capital Markets Starts Editas Medicine (EDIT) at Buy
-
Chardan Capital Markets Starts Intellia Therapeutics (NTLA) at Buy
-
Teladoc (TDOC): Management Confident on NDR - Chardan
-
La Jolla Pharmaceutical (LJPC) Prices 3.7M Common Stock Offering at $33.50/Share
-
La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock
-
HealthEquity, Inc (HQY) PT Raised to $53 at Chardan Capital Markets Following Q4 Beat and Positive Guidance
-
Regenxbio (RGNX) Reports Pricing of 3.7M Share Offering at $20.50
-
REGENXBIO Announces Pricing of Public Offering of Common Stock
-
Regenxbio (RGNX) Plans $75M Common Stock Offering
-
REGENXBIO Announces Proposed Public Offering of Common Stock
-
Chardan Capital Markets Reiterates Buy on Benefitfocus (BNFT) Following Analyst Day
-
Chardan Capital Markets Reiterates Buy on Cogent (COGT) Following 4Q
-
Profire Energy (PFIE) PT Raised to $2.15 at Chardan Capital Markets; Estimates Raised
-
Chardan Capital Maintains Buy Rating and $3.50 PT on 22nd Century Group (XXII) Ahead of Q4 Report
-
Chardan Capital Maintains Buy Rating and $10 PT on Vuzix Corp. (VUZI); 'Strong Start to 2017 from M300 and Toshiba'
-
Chardan Capital Reiterates Buy Rating and $11.50 PT on ORBCOMM (ORBC); 'Strong Backlog and Robust Pipeline'
-
Teladoc (TDOC) PT Raised to $28 at Chardan Capital Markets Following 4Q Top-Line and Bottom-Line Beats
-
La Jolla Pharma (LJPC) PT Raised to $90 at Chardan Capital Markets Following Robust LJPC-501 Phase 3 Topline Results
-
Chardan Capital Maintains Hold Rating and $1.50 PT on Novavax (NVAX) Following 4Q Report; New RSV F Clinical Data is Next Catalyst
-
Chardan Capital Markets Upgrades Globalstar (GSAT) to Buy
-
Chardan Capital Markets Starts OncoCyte Corp (OCX) at Buy
-
Chardan Capital Markets Reiterates Buy on NICE Systems (NICE) Following 4Q Report
-
Chardan Capital Reiterates Neutral Rating and $35 PT on DigitalGlobe (DGI) Following Takeover Reports
-
Teladoc (TDOC): More Confident After Management Meetings - Chardan
-
BioTime, Inc. Announces Closing of Public Offering of Common Stock
-
Chardan Capital Markets Remains Bullish on NICE Systems (NICE) Ahead of 4Q Report
-
Chardan Capital Markets Upgrades Sage Therapeutics (SAGE) to Neutral
-
Chardan Capital Markets Reiterates Buy on HealthEquity (HQY) Following Investor Call
-
BioTime (BTX) Prices 6.5M Common Stock Offering at $2.70/Share
-
BioTime, Inc. Announces Pricing of Public Offering of Common Stock
-
HealthEquity (HQY): Strong Preannouncement With Guidance In Line - Chardan
-
MYOS RENS Tech (MYOS) Reports $2.13M Registered Direct Offering of Common Stock
-
MYOS RENS Technology Inc. Announces $2,125,000 Registered Direct Offering
-
Pre-Open Movers 02/03: (PXLW) (DATA) (PTN) Higher; (DECK) (IDXG) (FEYE) (GPRO) (AMZN) Lower (more...)
-
Chardan Capital Markets Downgrades Clovis Oncology (CLVS) to Sell
-
Chardan Capital Markets Starts Social Reality (SRAX) at Buy, $9 PT
-
uniQure (QURE) Breakthrough Therapy Designation an 'Important Positive' - Chardan Capital Markets
-
Emergent BioSolutions (EBS): 3 Key Points From NDR - Chardan
-
KeyW Holding (KEYW) 8.5M Share Offering Prices at $10.50
-
KeyW Announces Pricing of Public Offering of Common Stock
-
KeyW (KEYW) Announces 8.5M Public Offering of Common Stock
-
KeyW Announces Public Offering of Common Stock

